Browse the evidence

Dual (GLP-1/GIP) and Triple (GLP-1/GIP/Glucagon) receptor agonists offer superior weight loss and metabolic benefits compared to GLP-1 mono-agonism by leveraging complementary mechanisms.

Newer multi-agonists (dual/triple) like retatrutide show much higher weight loss (up to 24%) than older GLP-1 drugs. They work by hitting multiple metabolic targets at once, which may be necessary for patients who don't respond sufficiently to GLP-1 alone.

Short-term time-restricted eating (8-hour window) leads to greater loss of trunk lean mass compared to an extended 12-hour eating window, although total body mass loss is similar.

While your muscle building capacity (MPS) stays the same, you might see a small drop in 'lean mass' on body scans during the first 10 days of an 8-hour eating window. This is likely due to fluid or organ mass changes, not actual muscle loss, especially since your muscle synthesis rates are unchanged. Don't panic if your strength doesn't drop.

Triple agonists targeting GLP-1, GIP, and Glucagon receptors (GCGR) offer additional metabolic benefits, including increased energy expenditure and weight loss, by combining the insulinotropic effects of incretins with the lipolytic and anorectic effects of glucagon.

For patients with Type 2 Diabetes and obesity who need more than standard treatment, triple-agonist medications (targeting GLP-1, GIP, and Glucagon) are in early development. These drugs aim to boost weight loss and energy expenditure by leveraging the body's natural hormonal responses to food. Because they are still in early trials, their long-term safety and optimal dosing are not yet fully established, but they represent a promising next step for complex metabolic cases.

Low-load blood flow restriction (LL-BFR) resistance training produces type I fiber hypertrophy that is at least equal to, and sometimes greater than, type II fiber hypertrophy, contrasting with high-load training which preferentially hypertrophies type II fibers.

To target slow-twitch (Type I) muscle fibers, use low loads (20-50% of your one-rep max) combined with blood flow restriction cuffs. Perform sets to near failure with short rest periods (30 seconds). This method can stimulate growth in these fibers as effectively as, or better than, heavy lifting, which typically favors fast-twitch fibers.

High-load resistance training (HL-RT) produces significantly greater muscle hypertrophy than low-load resistance training with blood flow restriction (LL-RT with BFR) in upper limb exercises.

When training upper body muscles (like biceps or shoulders) with blood flow restriction, you may not get as much muscle growth as you would with heavy weights. If your goal is maximum upper body size, high-load training might be more effective than BFR. However, BFR is still a viable option for rehabilitation or when heavy weights are not possible, just expect potentially smaller gains compared to heavy lifting.

Tirzepatide demonstrates potential for cardiovascular protection, including reduced risk of major adverse cardiovascular events (MACE-4) and improved lipid profiles, in patients with Type 2 Diabetes.

Beyond lowering blood sugar, Tirzepatide may improve heart health by lowering bad cholesterol and triglycerides and reducing the risk of heart attacks and strokes. This is particularly important for diabetic patients with existing heart risks.

Tirzepatide shows promise for treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by reducing liver fat content and improving liver enzymes, likely through indirect weight loss and metabolic effects.

For diabetics with fatty liver, Tirzepatide may help reduce liver fat and improve liver enzymes, likely by aiding weight loss and metabolic health. However, more specific clinical trials are needed to confirm its efficacy as a primary treatment for NASH.

Bariatric surgery results in greater weight loss and higher rates of type 2 diabetes remission compared to sleeve gastrectomy, and is associated with reduced nephropathy and major adverse cardiovascular events.

For individuals with severe obesity and type 2 diabetes who have not achieved remission with lifestyle changes or medications, bariatric surgery (particularly Roux-en-Y gastric bypass) can be a highly effective option. It offers greater weight loss and diabetes remission rates than other surgical options like sleeve gastrectomy, along with reduced heart and kidney risks, though it carries higher surgical risks.

Fasted cardiovascular exercise is commonly recommended by bodybuilding coaches (67%), primarily to synergize with fat-burning supplements like yohimbine and clenbuterol, despite systematic reviews showing no superiority over fed cardio for fat loss in general populations.

Bodybuilding coaches frequently prescribe fasted cardio (67% of respondents) not because it burns more fat than fed cardio, but to allow the use of fat-burning supplements like yohimbine or clenbuterol. If you are not using these specific supplements, fasted cardio offers no fat-loss advantage over fed cardio. Focus on total weekly energy expenditure and recovery.

Diets high in rapidly digestible carbohydrates increase the insulin-to-glucagon ratio, shifting energy partitioning toward adipose storage and away from metabolically active tissues, which triggers compensatory hunger and reduced metabolic rate.

To manage weight, focus on reducing rapidly digestible carbohydrates (refined grains, added sugars) to lower insulin levels. This prevents the hormonal trapping of energy in fat cells and reduces the biological drive to overeat and slow metabolism.

High-glycemic load (GL) diets reduce total energy expenditure (TEE) compared to low-carbohydrate or low-GL diets, even when calories and weight are matched.

When maintaining weight loss, choose lower-carbohydrate or lower-glycemic load foods to support a higher metabolic rate compared to high-carbohydrate diets.

A 12-month Mediterranean diet intervention in firefighters leads to modest but significant improvements in specific cardiometabolic markers, specifically body fat percentage and LDL cholesterol, at 6 months, though these effects may not persist or reach significance after multiple comparison corrections.

While the diet improves adherence, expect modest changes in body fat and LDL cholesterol, particularly in the first 6 months. Do not expect dramatic shifts in these specific markers, and be aware that statistical significance may be lost when accounting for multiple health metrics.

Lifestyle interventions (diet and exercise) combined with GLP-1 receptor agonists (GLP-1RAs) may mitigate gastrointestinal side effects and enhance weight loss, though their efficacy requires confirmation via randomized controlled trials.

If you are taking a GLP-1RA, do not abandon lifestyle changes. Focus on dietary strategies like smaller, lower-fat meals to manage nausea and other side effects. This may help you stay on the medication longer and potentially achieve greater weight loss, although more research is needed to confirm these benefits.

Weight loss of 20% or higher with newer GLP-1RAs raises concerns for nutritional deficiency and sarcopenia, necessitating monitoring similar to post-bariatric surgery care.

If you are losing a lot of weight (20% or more) on a GLP-1RA, ask your doctor about monitoring for nutritional deficiencies and muscle loss. You may need a dietitian to help you ensure you are getting enough protein and nutrients, similar to post-bariatric surgery guidelines.

In obese patients with preexisting hip or knee osteoarthritis, GLP-1 receptor agonist use is associated with a significantly reduced odds of conversion to total joint arthroplasty (THA and TKA) within one year, independent of weight loss.

If you are obese and have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist (like semaglutide or liraglutide) is associated with a lower risk of needing joint replacement surgery within a year, even if your weight doesn't change significantly. This suggests the drug may have direct protective effects on your joints, not just benefits from weight loss. Discuss this potential benefit with your doctor, especially if you are considering these medications for weight management or diabetes.

Bariatric surgery induces substantial and durable weight loss in adults with severe obesity, with 89.3% of patients achieving ≥20% weight loss in the short term (0-9 years) and 81.2% maintaining this loss in the long term (10-24 years).

For individuals with severe obesity (BMI ≥40 or ≥35 with health issues), bariatric surgery is the most effective method for achieving and maintaining significant weight loss. While lifestyle changes are crucial, they rarely result in the >20% weight loss seen with surgery. Surgery provides durable benefits for over a decade, making it a viable long-term solution for severe obesity.

GLP-1 receptor agonists (GLP-1RAs) promote significant weight loss and BMI reduction in people with HIV (PWH), with tirzepatide and longer treatment duration (>6 months) being the strongest predictors of achieving >5% weight loss.

If you have HIV and are struggling with weight gain, GLP-1 receptor agonists (like semaglutide or tirzepatide) are a proven, effective treatment option. The study shows that sticking with the medication for more than 6 months and reaching the maximum dose significantly increases your chances of losing more than 5% of your body weight. Tirzepatide, in particular, showed the strongest association with significant weight loss in this population.

Discontinuation of GLP-1 analogues for obesity is primarily driven by side effects (36%), logistical challenges (24%), and cost (23%), leading to significantly lower long-term weight loss compared to persistent users.

If you are taking a GLP-1 for weight loss, sticking with it is the most important factor for success. Most people stop due to side effects, cost, or logistics, not because the drug doesn't work. To stay on it, work with your doctor to titrate the dose slowly to minimize stomach issues, seek financial assistance if the cost is prohibitive, and use telemedicine to reduce logistical burdens. Persisters lose significantly more weight (nearly 18%) than those who quit early (12.6%).

High adherence to a low-carbohydrate diet score is associated with significantly lower diastolic blood pressure, lower triglyceride concentrations, and higher HDL cholesterol in obese adults.

For obese adults, adopting a dietary pattern that lowers carbohydrate intake and increases fat intake (a high LCD score) is associated with better blood pressure and lipid profiles, specifically lower triglycerides and higher HDL. However, simply shifting macros may not reduce body weight if carbohydrate intake remains above 50% of total energy.

High adherence to a low-carbohydrate diet score is associated with a reduced prevalence of metabolic syndrome in obese adults.

Adhering to a low-carbohydrate dietary pattern is linked to a lower likelihood of having metabolic syndrome in obese individuals, likely due to improvements in blood pressure and lipids.

Eloralintide (LY3841136), a selective amylin receptor agonist, promotes significant body weight loss primarily through fat mass reduction with favorable gastrointestinal tolerability compared to non-selective amylin agonists.

Eloralintide is a once-weekly injection that targets specific receptors to reduce appetite and food intake. In early trials, it led to modest but significant weight loss (up to 4.4% in 4 weeks) primarily by burning fat, with fewer stomach side effects than some competitors. It is currently in early clinical stages and not yet widely available.

Bodybuilding peak-week strategies involving carbohydrate supercompensation and acute water manipulation significantly increase the intracellular-to-extracellular water ratio (ICW/ECW) and phase angle, indicating fluid shifts from subcutaneous to intracellular compartments.

If you are a competitive bodybuilder, your peak week strategy of high carbohydrate intake combined with initial high water intake followed by a reduction can effectively shift water from under the skin into the muscles. This increases muscle fullness and definition (higher phase angle) even if your total body weight or total water volume decreases slightly. Monitor your bioelectrical impedance if possible to track this shift.

Even protein distribution is associated with lower-body muscular endurance, but not functional ability (gait speed or chair stand tests) in healthy women.

If your goal is muscular endurance (e.g., ability to perform repeated movements), spreading protein to meet relative targets (0.24 g/kg for <60yo, 0.4 g/kg for ≥60yo) per meal may help. However, do not expect this to directly improve your walking speed or daily functional tasks like chair stands if you are already healthy and active.

Frequent eating out of home (1-5 times/week or >6 times/week) is negatively correlated with daily vegetable and fruit intake and positively correlated with meat and aquatic product intake.

If you eat out frequently, you are likely consuming fewer fruits and vegetables and more meat/aquatic products than if you cooked at home. To counteract this, consciously prioritize vegetable-heavy dishes when dining out, or ensure your home-cooked meals are rich in produce to balance your weekly intake.